Treatment of Hepatitis C pharmacology presentation

RaufBalouch 0 views 8 slides Oct 15, 2025
Slide 1
Slide 1 of 8
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8

About This Presentation

In this File i have described The treatment of hepatitis C


Slide Content

Treatment of Hepatitis C By; Abdul Rauf Roll no; 16 Group Morning Subject Pharmacology

Hepatitis C is an  inflammation of the liver caused by the hepatitis C virus .  The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including liver cirrhosis and cancer. Globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year. WHO estimated that in 2022, approximately 242 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). INTRODUCTION

To Hepatitis C spread 4 Ways

Symptoms Fever Fatigue Loss of appetite Nausea and vomiting Abdominal pain- Dark urine Clay-colored bowel movements Joint pain- Jaundice

Treatment 5  Direct-acting antivirals (DAAs ) work by targeting different viral proteins to stop the hepatitis C virus (HCV) from multiplying

Elbasvir-grazoprevir (zepatier) Elbasvir-grazoprevir ( Zepatier ) is a combination medication used to treat chronic hepatitis C virus (HCV) genotypes 1 and 4. It works by combining an NS5A inhibitor (elbasvir) and an NS3/4A protease inhibitor (grazoprevir) to block viral replication at two different steps: Elbasvir prevents viral RNA replication and assembly , while grazoprevir prevents the cleavage of viral polyproteins needed for replication .

An inhibitor of the HCV NS5A protein, which is essential for viral RNA replication and the assembly of new virus particles .  Meshanism of Action Elbasvir :  Grazoprevir:   An inhibitor of the HCV NS3/4A protease, an enzyme that the virus needs to cut its polyprotein into smaller, functional proteins. By inhibiting this protease, grazoprevir prevents the maturation of viral proteins and stops viral replication.

Common Adverse Effects 8 Fatigue / feeling tired Headache Nausea Diarrhea Insomnia (difficulty sleeping) These are effects seen in a noticeable percentage of people (often ≥ 5%) in trials without ribavirin: Adverse Effects When Used With Ribavirin When Zepatier is given with ribavirin, additional effects are more likely, particularly: Anemia (low red blood cell count Shortness of breath (dyspnea) Rash or itching (pruritus) Abdominal pain